Skip to main content
TEYI PHARMACEUTICAL GROUP CO.,LTD logo

TEYI PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 002728 ISIN · CNE100001WK6 LEI · 300300ZUIZCFPGQWOZ61 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,597 across all filing types
Latest filing 2015-09-22 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002728

About TEYI PHARMACEUTICAL GROUP CO.,LTD

https://www.tczy.com.cn

TEYI PHARMACEUTICAL GROUP CO.,LTD. specializes in the research, development, manufacturing, and distribution of pharmaceutical products. The company's portfolio primarily consists of Chinese patent medicines and chemical drug preparations. Its flagship product, Zhike Bao Tablets, is widely recognized for treating chronic bronchitis and cough-related ailments. Beyond respiratory health, the group produces a diverse range of medications covering cardiovascular diseases, gastrointestinal disorders, and anti-infective treatments. Teyi Pharmaceutical operates modern production facilities and maintains a robust distribution network to serve healthcare providers and pharmacies. The company emphasizes the integration of traditional medicinal knowledge with modern pharmaceutical technology to enhance product efficacy and safety.

Recent filings

Filing Released Lang Actions
关于最近五年未被证券监管部门和交易所采取处罚或监管措施的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement from Guangdong Taicheng Pharmaceutical Co., Ltd. stating that in the past five years, the company has not been subject to any penalties or regulatory measures by securities regulatory authorities or exchanges. It includes a statement of compliance and governance but does not contain financial data, detailed reports, or meeting materials. The length is only 591 characters, indicating it is a brief regulatory announcement rather than a full report. It fits best under Regulatory Filings (RNS) as a compliance-related disclosure that does not fit other specific categories.
2015-09-22 Chinese
关于非公开发行股票申请文件反馈意见回复的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Guangdong Taicheng Pharmaceutical Co., Ltd. regarding the company's response to feedback from the China Securities Regulatory Commission (CSRC) on its application for a non-public issuance of shares. It discusses regulatory feedback and the company's reply, indicating it is related to capital raising activities. The document is short (613 characters) and serves as a public disclosure of the company's reply to regulatory feedback rather than the actual issuance or detailed financial data. Therefore, it fits best under Capital/Financing Update (CAP) as it pertains to financing activities and regulatory approval for share issuance.
2015-09-22 Chinese
2015年第二次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 2015 second extraordinary shareholders' meeting of Guangdong Taicheng Pharmaceutical Co., Ltd. It includes information about the meeting's convocation, attendance, voting results on specific proposals, and legal opinions confirming the validity of the meeting and voting process. The content focuses on the official results of shareholder votes at a general meeting, including percentages of shares voted for and against, and procedural compliance. There is no indication that this is a full annual or interim report, audit report, or other financial report. The document is not a proxy solicitation or a presentation but specifically reports the voting results of the shareholders' meeting. Therefore, the appropriate classification is Declaration of Voting Results & Voting Rights Announcements (DVA). The document length and detail support this classification with high confidence.
2015-09-18 Chinese
2015年第二次临时股东大会的法律意见书
Legal Proceedings Report Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the legality of the procedures and results of a specific shareholders' meeting (the 2015 second extraordinary general meeting) of Guangdong Taicheng Pharmaceutical Co., Ltd. It details the convening, attendance, voting procedures, and results of the meeting, and concludes on the legality and validity of these aspects. The document does not contain financial statements or financial performance data, nor is it a report of financial results or management discussion. It is not an announcement of voting results but a legal opinion on the meeting's legality. Therefore, it does not fit categories like Annual Report, Earnings Release, or Declaration of Voting Results. It is a legal proceedings related document providing an opinion on a corporate legal matter, which fits best under Legal Proceedings Report (LTR). The document length is under 5,000 characters, but it is a substantive legal opinion, not a mere announcement or certification, so it is not RPA or RNS.
2015-09-18 Chinese
独立董事关于公司聘任高级管理人员的独立意见
Board/Management Information Classification · 95% confidence The document is a formal statement from independent directors regarding the appointment of senior management personnel at Guangdong Taicheng Pharmaceutical Co., Ltd. It references compliance with relevant laws and regulations, and confirms the qualifications and appointment of two vice general managers. The document is short (745 characters) and focuses on management appointment opinions rather than financial data or report publication. This fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board or senior management.
2015-09-09 Chinese
关于副总经理辞职的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the resignation of the company's Vice General Manager. It details the resignation letter submission, the effective date, and the impact on company operations. There is no financial data, no mention of financial results, reports, or regulatory filings beyond the management change. This fits the category of Board/Management Information (MANG), which covers announcements of changes in senior management.
2015-09-09 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.